Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Neenah Paper to Present at the Bank of America Merrill Lynch 2013 Smid Cap Conference on May 7, 2013 to Neogen launches rapid tests for ractopamine

This site contains about 74,006 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   400   500   600   700   800   900   1,000   1,100   1,200   1,350   1,360   1,370   1,380   1,390   1,400   1,410   1,420   1,430   1,437   1,438   1,439   1,440   1,441   1,442   1,443   1,444   1,445   1,446   1,447   1,448   1,449   1,450   1,451   1,452   1,453   1,454   1,455   1,456   1,457   1,458   1,459   1,460   1,461   1,462   1,463   1,464   1,465   1,466   1,470   1,480   1,490   1,500   1,510   1,520   1,530   1,540   1,550   1,600   1,700   1,800   1,900   2,000   2,100   2,200   2,300   2,400   2,467 

2013/4/22
Neenah Paper to Present at the Bank of America Merrill Lynch 2013 Smid Cap Conference on May 7, 2013
Neenah Paper, Inc. (NYSE: NP) announced today that the Company will be presenting at the Bank of America Merrill Lynch 2013 Smid Cap Conference on May 7, 2013, at 8:45 a.m. EDT at Boston's Four Seasons Hotel.
View more Neenah Paper to Present at the Bank of America Merrill Lynch 2013 Smid Cap Conference on May 7, 2013 analysis
Sign-up for Neenah Paper to Present at the Bank of America Merrill Lynch 2013 Smid Cap Conference on May 7, 2013 investment picks
2013/4/26
Neenah Paper to Report First Quarter Earnings on May 8, 2013
Neenah Paper, Inc. (NYSE: NP) today announced it will issue a press release covering first quarter financial results on Wednesday, May 8, 2013, after the close of the New York Stock Exchange.
View more Neenah Paper to Report First Quarter Earnings on May 8, 2013 analysis
Sign-up for Neenah Paper to Report First Quarter Earnings on May 8, 2013 investment picks
2013/2/6
Neenah Paper to Report Fourth Quarter and Full Year Earnings on February 20, 2013
Neenah Paper, Inc. (NYSE: NP) today announced it will issue a press release covering fourth quarter and full year financial results on Wednesday, February 20, 2013, after the close of the New York Stock Exchange.
View more Neenah Paper to Report Fourth Quarter and Full Year Earnings on February 20, 2013 analysis
Sign-up for Neenah Paper to Report Fourth Quarter and Full Year Earnings on February 20, 2013 investment picks
2013/1/31
Neenah Purchases Premium Business Paper Brands From Southworth
Neenah Paper, Inc. (NYSE:NP) announced today that it has completed the purchase of certain premium business paper brands from the Southworth Company.
View more Neenah Purchases Premium Business Paper Brands From Southworth analysis
Sign-up for Neenah Purchases Premium Business Paper Brands From Southworth investment picks
2013/5/10
Negotiations Push Release of ResCap Examiner's Report to Monday
By Andrew R.
View more Negotiations Push Release of ResCap Examiner's Report to Monday analysis
Sign-up for Negotiations Push Release of ResCap Examiner's Report to Monday investment picks
2013/4/16
NEI Changes Name to UNICOM Engineering, Inc.
http://media.marketwire.com/attachments/201304/145580_UNICOMEngineeringMasterrgbLogo_300dpi.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1007314&ProfileId=051205&sourceType=1 CANTON, MA --
View more NEI Changes Name to UNICOM Engineering, Inc. analysis
Sign-up for NEI Changes Name to UNICOM Engineering, Inc. investment picks
2013/2/5
NeighborWorks America, Wells Fargo, Help 1,600 Successfully Buy Homes Through 'LIFT' Programs
WASHINGTON and SAN FRANCISCO, Feb.
View more NeighborWorks America, Wells Fargo, Help 1,600 Successfully Buy Homes Through 'LIFT' Programs analysis
Sign-up for NeighborWorks America, Wells Fargo, Help 1,600 Successfully Buy Homes Through 'LIFT' Programs investment picks
2013/5/30
Neiman Owners Rebuffed Overture for Saks Merger
Neiman Marcus Group Inc. spurned a recent proposal in which buyout firm KKR & Co.
View more Neiman Owners Rebuffed Overture for Saks Merger analysis
Sign-up for Neiman Owners Rebuffed Overture for Saks Merger investment picks
2013/5/26
Neiman Scaling Back Physical Presence in China
Neiman Marcus Group Inc. is scaling back its physical operations in China amid a broader slowdown in the country for luxury goods.
View more Neiman Scaling Back Physical Presence in China analysis
Sign-up for Neiman Scaling Back Physical Presence in China investment picks
2013/5/10
Neiman To Court Sovereign Wealth Funds
Neiman Marcus Group Inc. is planning overtures to a handful of sovereign-wealth funds about a possible buyout of the luxury retailer, said people familiar with deliberations.
View more Neiman To Court Sovereign Wealth Funds analysis
Sign-up for Neiman To Court Sovereign Wealth Funds investment picks
2013/2/5
Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC)
SAN FRANCISCO , Feb.
View more Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) analysis
Sign-up for Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) investment picks
2013/6/3
Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
NKTR-214 Demonstrates Improved Efficacy and Better Tolerability in Aggressive and Resistant Preclinical Melanoma Model SAN FRANCISCO , June 3, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, an investigational cancer immunotherapy which targets the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers.
View more Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting analysis
Sign-up for Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting investment picks
2013/6/1
Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
CHICAGO and SAN FRANCISCO , June 1, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it presented a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of breast cancer.
View more Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting analysis
Sign-up for Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting investment picks
2013/5/9
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
SAN FRANCISCO , May 9, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2013 .
View more Nektar Therapeutics Reports Financial Results for the First Quarter of 2013 analysis
Sign-up for Nektar Therapeutics Reports Financial Results for the First Quarter of 2013 investment picks
2013/2/28
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
SAN FRANCISCO , Feb.
View more Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results analysis
Sign-up for Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results investment picks
2013/3/1
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
SAN FRANCISCO , March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr.
View more Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston analysis
Sign-up for Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston investment picks
2013/5/16
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
SAN FRANCISCO , May 16, 2013 /PRNewswire/ --   Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W.
View more Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City analysis
Sign-up for Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City investment picks
2013/5/30
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
SAN FRANCISCO , May 30, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W.
View more Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City analysis
Sign-up for Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City investment picks
2013/5/2
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , May 2, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013 , after the close of U.S.-based financial markets.
View more Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets analysis
Sign-up for Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets investment picks
2013/2/13
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Feb.
View more Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets analysis
Sign-up for Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets investment picks
2013/5/9
Nelnet Reports First Quarter 2013 Results
- GAAP net income $1.46 per share - Net income $1.34 per share, excluding derivative market value and foreign currency adjustments, up 21 percent from first quarter 2012 - Total student loan servicing volume now exceeds $112 billion LINCOLN, Neb.
View more Nelnet Reports First Quarter 2013 Results analysis
Sign-up for Nelnet Reports First Quarter 2013 Results investment picks
2013/2/28
Nelnet Reports Fourth Quarter 2012 Results
- GAAP net income $1.20 per share - Net income $1.05 per share, excluding impairment, derivative market value, and foreign currency adjustments - Purchased $3.0 billion of student loans in the quarter - Repurchased 746,459 shares in the quarter; 153,908 shares in 2013 LINCOLN, Neb.
View more Nelnet Reports Fourth Quarter 2012 Results analysis
Sign-up for Nelnet Reports Fourth Quarter 2012 Results investment picks
2013/4/23
Nelnet to Announce First Quarter Results on May 9
LINCOLN, Neb.
View more Nelnet to Announce First Quarter Results on May 9 analysis
Sign-up for Nelnet to Announce First Quarter Results on May 9 investment picks
2013/2/6
Nelnet to Announce Fourth Quarter and Year-End Results on Feb. 28; Dividend Approved
LINCOLN, Neb.
View more Nelnet to Announce Fourth Quarter and Year-End Results on Feb. 28; Dividend Approved analysis
Sign-up for Nelnet to Announce Fourth Quarter and Year-End Results on Feb. 28; Dividend Approved investment picks
2013/2/26
Nelson Promoted to President of the Commercial Segment of Oshkosh Corporation
Oshkosh Corporation (NYSE: OSK) announced today that Brad Nelson has been promoted to Oshkosh Corporation senior vice president and president of the Commercial business segment.
View more Nelson Promoted to President of the Commercial Segment of Oshkosh Corporation analysis
Sign-up for Nelson Promoted to President of the Commercial Segment of Oshkosh Corporation investment picks
2013/6/10
Neogen announces Bohannon retirement, successor named
LANSING, Mich.
View more Neogen announces Bohannon retirement, successor named analysis
Sign-up for Neogen announces Bohannon retirement, successor named investment picks
2013/3/20
Neogen Corporation Announces 3rd Quarter Results Conference Call
LANSING, Mich.
View more Neogen Corporation Announces 3rd Quarter Results Conference Call analysis
Sign-up for Neogen Corporation Announces 3rd Quarter Results Conference Call investment picks
2013/3/25
Neogen Corporation Announces 3rd Quarter Results Conference Call
LANSING, Mich.
View more Neogen Corporation Announces 3rd Quarter Results Conference Call analysis
Sign-up for Neogen Corporation Announces 3rd Quarter Results Conference Call investment picks
2013/5/6
Neogen launches comprehensive cattle genomic test
LANSING, Mich.
View more Neogen launches comprehensive cattle genomic test analysis
Sign-up for Neogen launches comprehensive cattle genomic test investment picks
2013/3/21
Neogen launches rapid tests for ractopamine
LANSING, Mich.
View more Neogen launches rapid tests for ractopamine analysis
Sign-up for Neogen launches rapid tests for ractopamine investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Neenah Paper to Present at the Bank of America Merrill Lynch 2013 Smid Cap Conference on May 7, 2013 to Neogen launches rapid tests for ractopamine
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.